European acne guidelines differ significantly from their American counterparts, most notably in antibiotic selection, isotretinoin dosing, how acne is classified, and when combination therapies should begin. The 2025 EuroGuiDerm update and recent European Medicines Agency approvals establish these distinctions clearly: European dermatologists favor doxycycline over minocycline, prescribe isotretinoin at roughly half the daily dose used in the United States (0.3-0.5 mg/kg rather than 1.0 mg/kg), and recommend starting combination topical therapy—benzoyl peroxide paired with a retinoid or antibiotic—for even mild-to-moderate acne rather than trying monotherapy first. A patient seeking acne treatment in Berlin or London will receive different initial recommendations than that same patient would in New York or Los Angeles, based on evidence-based regional preferences.
These differences matter because they influence treatment timelines, side effect profiles, and overall efficacy. If you’ve read American acne protocols or heard advice from U.S.-based dermatologists but live in Europe, you may wonder whether those recommendations apply to you. This article examines the major distinctions in European acne guidelines, explains the reasoning behind them, and clarifies what you should expect if your dermatologist is following European evidence-based standards.
Table of Contents
- How Do European Guidelines Classify Acne Differently?
- Why Do European Doctors Prefer Doxycycline Over Minocycline?
- What Changed With Isotretinoin Dosing in European Practice?
- Should You Start With Combination Topical Therapy Right Away?
- What Is Clascoterone and Why Is It Important to European Treatment Guidelines?
- How Do Hormonal Therapies Fit Into European Acne Treatment?
- What Does This Mean for Treatment Timelines and Outcomes?
- Conclusion
How Do European Guidelines Classify Acne Differently?
European acne guidelines use a morphology-based classification system that differs fundamentally from the american approach. Rather than categorizing acne simply as mild, moderate, or severe, European dermatologists classify acne by lesion type: comedonal (blackheads and whiteheads only), mild-to-moderate papulopustular (red bumps and pustules), severe papulopustular or moderate nodular (larger inflamed lesions), and severe nodular or conglobate (extensive deep cysts and interconnected lesions). This system is more specific about what’s actually present on the skin and therefore guides treatment selection more precisely.
The practical difference is that a person with 20 whiteheads and blackheads on the cheeks would be classified as having comedonal acne—even if the total lesion count seems “moderate” by American standards. Under European guidelines, this patient receives a different first-line treatment (topical retinoid alone, or benzoyl peroxide and a retinoid combined) than someone with the same number of red papules. By contrast, American guidelines might place both patients in the “mild-to-moderate” category and offer more flexibility in initial approach.
Why Do European Doctors Prefer Doxycycline Over Minocycline?
European guidelines explicitly recommend doxycycline and lymecycline as the systemic antibiotics of choice for acne, actively discouraging minocycline and standard tetracycline. This preference stems from efficacy data, side effect profiles, and long-term safety concerns. Doxycycline has stronger evidence for clinical efficacy and a lower risk of adverse effects compared to minocycline, which has been associated with drug-induced lupus, blue-gray skin discoloration, and hepatotoxicity when used long-term. However, if doxycycline is not tolerated—for instance, if a patient experiences severe esophageal irritation or photosensitivity—European guidelines do permit alternatives.
But minocycline is not considered equivalent; it’s deprioritized in favor of doxycycline or lymecycline. The EuroGuiDerm 2025 update also warns against azithromycin, which the EMA committee advised against using for acne due to insufficient evidence of efficacy. This is a notable divergence from some American practices, where azithromycin still appears in treatment discussions as an alternative. In Europe, it’s essentially off the table for routine acne care.
What Changed With Isotretinoin Dosing in European Practice?
One of the most striking differences between European and American isotretinoin protocols is dose intensity. American guidelines have long permitted daily doses of up to 1.0 mg/kg of body weight, with the goal of achieving cumulative dosing targets (typically 120-150 mg/kg) to minimize relapse risk. European guidelines recommend substantially lower daily doses: 0.3 to 0.5 mg/kg per day, with treatment duration extending to at least 6 months or longer to reach similar cumulative targets.
The rationale for lower daily dosing is twofold: reducing side effects (dryness, joint pain, potential for elevated lipids) during the treatment course and spreading the dose over a longer timeframe to potentially improve tolerability. A 70-kilogram patient, for example, would receive approximately 21-35 mg daily in Europe versus potentially 70 mg daily in the U.S. This means slower initial symptom resolution but often better compliance and fewer treatment interruptions due to side effects. The lower-dose strategy acknowledges that isotretinoin’s benefits come from cumulative exposure over time; there’s no evidence that higher daily doses improve ultimate cure rates, yet they do increase daily burden.
Should You Start With Combination Topical Therapy Right Away?
European guidelines recommend initiating treatment for mild-to-moderate acne with combination topical therapy rather than monotherapy. The standard approach is benzoyl peroxide combined with either a topical retinoid (such as tretinoin, adapalene, or tazarotene) or a topical antibiotic. This “combination-first” stance differs from some American guidance, which suggests trying benzoyl peroxide alone or other single agents before adding a second ingredient. The evidence supporting combination therapy is strong: dual agents address acne through different mechanisms simultaneously (benzoyl peroxide kills bacteria and reduces comedones, while retinoids normalize skin cell turnover and reduce inflammation), leading to faster clinical improvement.
For most European dermatologists, the cost and complexity of two topical products are outweighed by the superior results and the reduced likelihood of needing oral antibiotics. However, combination therapy does increase the risk of irritation, particularly when starting a retinoid. Patients must be counseled to begin slowly (perhaps twice weekly, building up), use sunscreen daily, and expect 8-12 weeks for full benefit. If irritation is severe or the patient is very sensitive-skinned, stepwise initiation (monotherapy for 2-4 weeks, then adding a second agent) may be necessary.
What Is Clascoterone and Why Is It Important to European Treatment Guidelines?
In August 2025, the European Medicines Agency recommended approval for clascoterone (brand name Winlevi), a novel topical androgen receptor inhibitor. The European Commission granted full marketing authorization on October 21, 2025, making clascoterone available for acne treatment in adolescents 12 years and older and in adults. This is significant because clascoterone offers a new mechanism of action—directly blocking the effects of androgens on sebaceous glands—without the systemic hormonal effects of oral contraceptives or spironolactone.
Clascoterone represents an important addition to the topical arsenal, particularly for hormonally driven acne in women who cannot or prefer not to use oral hormonal therapies. It’s applied topically (avoiding the systemic exposure of pills) and has a favorable safety profile in clinical trials. However, it’s a newer agent, and long-term real-world data are still accumulating. European dermatologists now have the option to offer this medication, but it’s not yet positioned as a first-line agent ahead of retinoids and benzoyl peroxide—rather, it’s a valuable option for specific patient profiles, such as those with clear hormonal drivers or intolerance to existing topicals.
How Do Hormonal Therapies Fit Into European Acne Treatment?
European guidelines acknowledge hormonal therapy—oral contraceptives and spironolactone—as legitimate second-line options for women with hormonally influenced acne. However, the threshold for recommending hormonal therapy is higher in European practice than in some American settings. Hormonal therapy is typically considered after topical and/or oral antibiotic treatment has been optimized, or for patients with clear signs of hormonal drivers (acne flares around menstruation, lesions concentrated on the jawline and neck, or elevated androgen labs).
The European approach reflects a preference for evidence-based stratification: not every woman with acne needs hormonal modification, and unnecessary systemic hormone exposure carries its own risks. For women with confirmed hormonal acne—particularly those with polycystic ovary syndrome or irregular cycles—hormonal therapy is a rational choice and is endorsed by European guidelines. But the starting point remains topical combination therapy or oral antibiotics, with hormonal therapy as a thoughtful second step rather than an early reflex.
What Does This Mean for Treatment Timelines and Outcomes?
Because European guidelines favor combination topical therapy upfront and lower-dose isotretinoin protocols, the timeline for acne improvement may differ from what American patients experience. Starting with dual topical agents (benzoyl peroxide plus a retinoid) often requires 8-12 weeks to show meaningful results, whereas some American approaches emphasize quicker escalation to oral antibiotics or higher-dose retinoid therapy. For mild-to-moderate acne, this more gradual approach is supported by evidence and often avoids unnecessary systemic therapy.
Looking ahead, the approval of clascoterone and the 2025 EuroGuiDerm update suggest that European acne care is expanding to include more targeted, mechanistically diverse options. The field is moving toward earlier, more aggressive topical combination therapy (to avoid antibiotics when possible), selective use of systemic agents (doxycycline and lymecycline preferred), and lower-intensity isotretinoin protocols that balance efficacy with tolerability. For patients in Europe, this means more choices and more personalized treatment plans; for those reading American-centric acne advice, it’s important to recognize that geography and guideline source matter.
Conclusion
The European approach to acne treatment reflects a distinct evidence-based philosophy that prioritizes combination topical therapy, favors specific systemic antibiotics (doxycycline and lymecycline), uses lower isotretinoin doses over longer durations, and excludes agents like azithromycin due to insufficient efficacy data. If you’re receiving acne care in Europe or consulting European dermatology standards, expect treatment recommendations that differ in detail—though not necessarily in overall outcome—from those you might read in American guidelines or social media influenced by U.S. practices.
Understanding these differences helps you have informed conversations with your dermatologist and realistic expectations for your treatment timeline. European guidelines are evidence-based and rigorous; the differences from American guidelines reflect genuine clinical judgment and regional data, not outdated thinking. Whether you’re starting topical combination therapy, considering an antibiotic, or contemplating isotretinoin, knowing what your regional guidelines emphasize will help you understand the logic behind your doctor’s recommendations and make confident decisions about your acne treatment.
